Single jab Sputnik Light shows 70% efficacy against Delta: RDIF – ET HealthWorld

Single jab Sputnik Light shows 70% efficacy against Delta: RDIF – ET HealthWorld


Single jab Sputnik Light shows 70% efficacy against Delta: RDIFThe Russian sovereign fund RDIF and Gamelya Center on Wednesday announced that the one-shot Sputnik Light vaccine has shown 70% effectiveness against the Delta variant of coronavirus three months after inoculation.

Gamelya also said the single jab is more than 75% effective among subjects under the age of 60. It also added that Sputnik Light provides much higher efficacy against severe disease and hospitalizations.

Gamelya said the efficacy was based on data from 28,000 participants who received a dose of Sputnik Light, compared with a control group of 5.6 million individuals who were not vaccinated.

The data used in the study was collected in July 2021 in Moscow. Gamelya said it has submitted the data to non peer reviewed medical journal medRxiv.

Kirill Dmitriev, CEO of RDIF said that Sputnik Light will be positioned as both a standalone vaccine as well as booster to other vaccines.

Dmitriev said that the mix and match studies are ongoing in Russia, Argentina, Azerbaijan and UAE, among others.

Dmitriev added that the initial results from the study to evaluate the immune response and safety of heterogeneous regimens combining Sputnik Light and vaccines produced by AstraZeneca, Sinopharm and Moderna in the city and province of Buenos Aires, as well as the San Luis, Cordoba and La Rioja provinces, confirmed a high safety profile of combinations with no serious adverse events.

The preliminary results of the combined use of the AstraZeneca vaccine and Sputnik Light from a clinical trial began in February in Azerbaijan demonstrated that antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of volunteers with good safety.

Sputnik Light has been authorized in more than 15 countries with the registration process ongoing in a further 30 countries. Sputnik Light will be produced by RDIF’s international partners in more than 10 countries (India, China, South Korea, Vietnam, Mexico, Argentina, Serbia, Turkey, etc.). This includes the Serum Institute of India, the world’s largest vaccine producer.

In India, the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation has recommended RDIF partner Dr Reddy’s to conduct Phase III clinical trials of Russia’s single dose COVID-19 vaccine Sputnik Light.

Dmitriev said RDIF is working with the India government to include Sputnik Light in its vaccination programme.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *